Association of overexpressed proline-directed protein kinase Fa with chemoresistance, invasion, and recurrence in patients with bladder carcinoma

Cancer

Volumn 95, Issue 4, 2002, Pages 775-783

  Hsueh, Sheng Fen ^a   Lai, Ming Tsung ^a   Yang, Chuan Ching ^a   Chung, Yuan Chiang ^a   Hsu, Chih Ping ^a   Peng, Chien Chung ^a   Fu, Hsiao Hui ^a   Cheng, Yung Ming ^b   Chang, King Jen ^b   Yang, Shiaw Der ^a  

^a NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Bladder carcinoma; Chemosensitivity; Invasion; Proline directed protein kinase; Recurrence

Indexed keywords

BLEOMYCIN; PACLITAXEL; PROLINE DIRECTED PROTEIN KINASE FA; PROTEIN KINASE; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CARCINOMA; CANCER CELL CULTURE; CANCER INVASION; CANCER RECURRENCE; CANCER RESISTANCE; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA;

ADULT; AGED; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; TUMOR CELLS, CULTURED; URINARY BLADDER NEOPLASMS;

EID: 0037103089     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.10731     Document Type: Article

References (21)

1. Global cancer statistics
2. Bladder cancer: State-of-the-art care
3. Bladder cancer: Twenty years of progress and the challenges that remain
4. A combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of Stage TaT1 bladder cancer
5. Swedish Council of Technology Assessment in Health Care. A systematic overview of chemotherapy effects in urothelial bladder cancer
6. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: A randomised controlled trial. International collaboration of trialists
7. An overview of the treatment of superficial bladder cancer. Intravesical chemotherapy
8. A/GSK-3α correlates with human thyroid tumor cell dedifferentiation
9. A/GSK-3α (a proline-directed kinase and a regulator of protooncogenes) with human cervical carcinoma dedifferentiation/progression
10. A/GSK-3α (a proline-directed protein kinase) correlates with human hepatoma dedifferentiation/progression
11. A/GSK-3α in well- and poorly-differentiated human prostate carcinoma cells
12. A expression inhibits the growth of human chronic myeloid leukemia cells
13. A systemically inhibits the growth of human acute leukemia cells
14. A enhances chemosensitivity in human prostate cancer cells
15. A potentiates apoptotic induction and greatly enhances chemosensitivity in human acute lymphoblastic leukemia cells
16. The relation of the preoperative estimate to the pathologic demonstration of the extent of vesical neoplasms
17. Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen
18. A expression potentiates erythroid differentiation of human leukemia cells
19. A rapid in vitro assay for quantitating the invasive potential of tumor cells
20. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell killing